Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience

Abstract

We investigated the incidence, risk factors, and clinical outcomes of cytomegalovirus (CMV) disease in patients with B-cell lymphoma treated with a bendamustine-containing regimen. The incidence of CMV disease was analyzed after starting treatment with 139 regimens in 126 patients. Clinically significant CMV disease was observed in seven patients. The median duration between bendamustine initiation and the diagnosis of CMV disease was 69 d (range, 40–233), and the median of cycles completed at onset was 2 (range, 1–6). Furthermore, the incidence of CMV disease was significantly higher in the elderly patients than that in the younger patients. The target organs of CMV disease were the liver, gastrointestinal tract, lungs, and retinas. Antiviral therapy was administered to all patients. However, the recurrence of CMV disease was observed in two patients. This study provides information that could contribute to clinicians’ decision-making on lymphoma therapy using bendamustine.

Keywords:

• Cytomegalovirus
• malignant lymphoma
• bendamustine

Acknowledgments

The authors thank Ms. Sachiyo Mazume and Ms. Miharu Watanabe for collecting patient data and making this study possible.

Ethical approval

All study procedures followed the Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional Review Boards of Nihon University Itabashi Hospital approved this study (RK-220614-9). Written informed consent was not required due to the retrospective nature of this study.

Disclosure statement

Katsuhiro Miura received honoraria from SymBio Pharmaceuticals and Chugai Pharmaceutical. Hiromichi Takahashi received speaker fees from SymBio Pharmaceuticals and Chugai Pharmaceutical. Yoshihiro Hatta received honoraria from SymBio Pharmaceuticals and Chugai Pharmaceutical. Hideki Nakamura received a scholarship fund from Chugai Pharmaceutical.

Additional information

Funding

This study was funded by the Japan Blood Products Organization.